ImmunoGen, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ImmunoGen, Inc., a biotechnology company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, operates as a subsidiary of AbbVie Inc. following its acquisition in February 2024. The company offers ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class FRα-directed ADC approved for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received one to three prior systemic treatments; IMGN151, a next-generation anti-FRα ADC in Phase 1 for ovarian and other solid tumors; pivekimab sunirine, a CD123-targeting ADC in Phase 2 for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia; and preclinical and early-stage assets including IMGC936 targeting ADAM9. Founded in 1981 and headquartered in Waltham, Massachusetts, ImmunoGen targets solid tumors and hematologic malignancies, with therapies leveraging its proprietary Targeted Antibody Payload technology to deliver cytotoxic payloads selectively to cancer cells expressing specific antigens. Recent developments include AbbVie's completion of the $10.1 billion acquisition of ImmunoGen on February 12, 2024, integrating its ADC pipeline into AbbVie's oncology portfolio; full FDA approval of ELAHERE in March 2024 based on confirmatory trial data demonstrating progression-free and overall survival benefits; and AbbVie's announcement in September 2025 of plans to launch ELAHERE in the United Kingdom at a list price aligned with the U.S. market.
Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research
AbbVie Cuts Its Guidance on ImmunoGen Deal
AbbVie's stock dips premarket after it lowers Q1 guidance to reflect dilutive impact of ImmunoGen deal close
AbbVie Completes Acquisition of ImmunoGen
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry
Cramer names biopharma companies to watch as industry mergers start to pile up
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy
Best Momentum Stocks to Buy for January 4th
New Strong Buy Stocks for January 4th
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
3 Stocks at the Forefront of Medical Innovation
5 Reasons to be Bullish into 2024
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
Market Movers: Why Big Players Are Investing Millions in These 3 Stocks
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout